

PATENT SPECIFICATION

Rec'd CT/PT 1419 221 07 JUL 2005

1 419 221

- (21) Application No. 2457/74 (22) Filed 18 Jan. 1974
 (61) Patent of Addition to No. 1 351 238 dated 9 June 1971
 (44) Complete Specification published 24 Dec. 1975
 (51) INT CL² C07C 177/00; A61K 31/00; C08B 37/16
 (52) Index at acceptance
 C2C 1175 1176 200 225 227 22X 22Y 29X 29Y 30Y 351
 353 360 362 363 366 367 36Y 389 623 625 628
 633 643 652 658 662 790 79Y BW UF
 C3U 2F 4L 4X
 (72) Inventors MASAKI HAYASHI and ATSUNOBU ISHIHARA



(54) CLATHRATE PROSTAGLANDINS AND COMPOSITIONS CONTAINING SAME

- (71) We, ONO PHARMACEUTICAL CO. LTD., a Japanese Body Corporate, of 14 Doshomachi 2-Chome, Higashiku, Osaka 541, Japan, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—
- This invention relates to cyclodextrin clathrates of prostaglandins or derivatives thereof, to a process for producing such clathrates and to pharmaceutical compositions containing them. It is an improvement in or modification of the invention described and claimed in the specification of our Application No. 19785/71 (now Serial No. 1,351,238).
- In the specification of Application No. 19785/71 (now Serial No. 1,351,238) we have claimed cyclodextrin clathrates of prostaglandins or of derivatives of prostaglandins, and specifically the β -cyclodextrin clathrates of PGE₁ alcohol, PGE₁ decyl ester, α -methyl-PGE₁, PGE₂, PGE₂ decyl ester, PGE₂ 9-ethoxycarbonylnonyl ester, α -methyl-PGE₂, 15-methyl-PGE₂, 16-methyl-PGE₂(B), 17-methyl-PGE₂(B), 16-methyl-PGE₂(B) alcohol, 16-methyl-PGE₂(B) decyl ester, PGF_{2 α} , PGA₂ and PGA₂ decyl ester, the β -cyclodextrin clathrate of 9-oxo-15 α -hydroxyprosta-5-cis,11,13-trans-trienoic acid, and the α -cyclodextrin clathrates of PGE₂ and PGE₁ alcohol. The cyclodextrin clathrates of prostaglandins and derivatives thereof are solid, white powdery substances much more stable than the prostaglandins themselves, and this stability is of substantial importance in the formulation of pharmaceutical compositions for therapeutic applications, the pharmacological properties of the prostaglandins or derivatives thereof not being impaired by the formation of clathrates.
- As a result of further research and experimentation, we have prepared cyclodextrin clathrates of other prostaglandins, and the present invention is concerned with the hitherto unprepared cyclodextrin clathrates of PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1 α} and PGA₁, and more particularly the β -cyclodextrin clathrates of said prostaglandins, which all possess outstanding pharmacological properties, and are highly stable. It is to be understood herein-after that the expression "cyclodextrin clathrates of prostaglandins of the present invention" means the cyclodextrin clathrates of PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1 α} and PGA₁ only.
- The explanation of the suffix "(B)" after "16-methyl-PGE₁" is as follows:—
- When 16-methyl-PGE₁ is prepared a mixture of four stereoisomers is obtained due to the configuration of the hydroxy and methyl groups on the C-15 and C-16 carbon atoms respectively. The product when subjected to chromatography on a silica gel column can be divided into two portions, one portion having the higher polarity is termed "16-methyl-PGE₁(B)"; its stereo-configuration being unknown.
- A similar explanation for the suffix "(B)" after "17-methyl-PGE₁" applies.
- The percentage of prostaglandin in the cyclodextrin clathrates of prostaglandins of the present invention can vary considerably, but is suitably from 2% to 12% by weight. The cyclodextrin forming the clathrates can be α -, β - or γ -cyclodextrin, or a mixture of any two or three of them, but preferably β -cyclodextrin is used.
- The cyclodextrin clathrates of prostaglandins of the present invention can be prepared by reacting cyclodextrin with PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1 α} or PGA₁.
- In preparing the clathrate compounds, cyclodextrin is preferably dissolved in water and/or in an organic solvent which is miscible with water and the solution added to a said prostaglandin dissolved in an organic solvent which is miscible with water, e.g. ethanol.

[Price 33p]

BEST AVAILABLE COPY

After the mixture is heated, the clathrate product may be obtained by concentrating the mixture under reduced pressure or leaving it to cool. Preferably 4 to 12 moles of cyclodextrin are used for each mole of prostaglandin. The mixing ratio of organic solvent with water may be suitably varied according to the solubilities of the starting materials and clathrate products. Due to the low thermal stabilities of the prostaglandin molecules, it is preferable to conduct the reaction at a temperature below 70° C. In the case of the PGE compounds, the preferred reaction temperature is 20–60° C.

The invention will be illustrated by the following Examples.

EXAMPLE 1.

A solution prepared by heating and dissolving 248 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 18.0 mg. of PGE₁ in 0.4 ml. of ethanol. After the mixture was heated to dissolution at 60° C., it was cooled to room temperature to obtain a precipitate. After standing overnight at room temperature, the precipitate was recovered by filtration and washed with 50% aqueous ethanol and dried under reduced pressure to obtain 203 mg. of the desired clathrate product. The content of PGE₁ in the product was 7.8%.

EXAMPLE 2.

A solution prepared by heating and dissolving 253 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 18.1 mg. of PGF_{1 α} in 0.4 ml. of ethanol. The mixture was heated to dissolution at 60° C., and then treated in the same manner as described in Example 1 to obtain 211 mg. of the desired clathrate product. The content of PGF_{1 α} in the product was 2.4%.

EXAMPLE 3.

A solution prepared by heating and dissolving 240 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 16.8 mg. of PGA₁ in 0.8 ml. of ethanol. The mixture was heated to dissolution at 60° C., and then treated in the same manner as described in Example 1 to obtain 183 mg. of the desired clathrate product. The content of PGA₁ in the product was 7.6%.

EXAMPLE 4.

A solution prepared by heating and dissolving 240 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 18.4 mg. of 15-methyl-PGE₁ in 0.4 ml. of ethanol. The mixture was heated

to dissolution at 60° C. and then treated in the same manner as described in Example 1 to obtain 195 mg. of the desired clathrate product. The content of 15-methyl-PGE₁ in the product was 2.1%.

EXAMPLE 5.

A solution prepared by heating and dissolving 245 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 18.5 mg. of 16-methyl-PGE₁(B) in 0.4 ml. of ethanol. The mixture was heated to dissolution at 60° C. and then treated in the same manner as described in Example 1 to obtain 170 mg. of the desired clathrate product. The content of 16-methyl-PGE₁(B) in the product was 10.2%.

EXAMPLE 6.

A solution prepared by heating and dissolving 250 mg. of β -cyclodextrin in 2.8 ml. of water was added to a solution prepared by dissolving 18.9 mg. of 17-methyl-PGE₁(B) in 0.4 ml. of ethanol. The mixture was heated to dissolution at 60° C., and then treated in the same manner described in Example 1 to obtain 168 mg. of the desired clathrate product. The content of 17-methyl-PGE₁(B) in the product was 9.8%.

In all of the above Examples, the clathrate compounds obtained were white powdery substances and their infrared spectra showed absorptions of carbonyl groups at 1710–1740 cm⁻¹ in the case of the PGEs and PGA₁. The binding ratios of the prostaglandins with cyclodextrin in the clathrates (i.e. content of prostaglandin in the products) were determined by quantitative analysis of the prostaglandins in the clathrate compounds. The quantitative analysis was conducted in the following manner:—PGA₁ and the PGE₁ compounds were isomerized with alkali to PGB compounds and the resulting absorption values in UV spectra were determined at wavelength 278 m μ . In the case of PGF_{1 α} , a contraction of guinea pig colon was employed in the determination.

It was confirmed by heat stability tests that the cyclodextrin clathrates of prostaglandins of the present invention have better, or substantially better, stability than the original prostaglandins, and this improvement in stability is particularly noticeable in respect of the PGE₁ compounds.

The following Table shows the contents of the various PGs in clathrate compounds of the present invention and the results of stability tests when the clathrates and original prostaglandins were heated at 106 \pm 4° C.

TABLE

Prostaglandin	Content*	Heat Stability**		
		1 hour	3 hours	8 hours
PGE ₁ -β-CD	7.8	98.0	91.2	90.3
PGE ₁		80.2	57.2	28.2
15-methyl-PGE ₁ -β-CD	2.1	88.2	87.8	84.0
15-methyl-PGE ₁		68.0	48.3	40.6
16-methyl-PGE ₁ (B)-β-CD	10.2	96.5	92.0	86.2
16-methyl-PGE ₁ (B)		73.2	63.5	48.0
17-methyl-PGE ₁ (B)-β-CD	9.8	97.8	97.5	97.0
17-methyl-PGE ₁ (B)		75.3	68.2	61.2
PGF _{1α} -β-CD	2.3	100	100	99
PGF _{1α}		100	99	99
PGA ₁ -β-CD	7.6	99.8	98.8	98.0
PGA ₁		99.5	98.3	95.0

"CD" is an abbreviation for "cyclodextrin clathrate".

* The figures indicate the percentage (w/w) of prostaglandin in the clathrates.

** The figures indicate the percentage of prostaglandin remaining stable at 106°±4°C.

As the cyclodextrin clathrates of prostaglandins of the present invention, which possess the pharmacological properties of the original prostaglandins, are white powdery substances and are easy to handle they may be employed in various pharmaceutical formulations, e.g. injectable compositions, tablets, aerosols, powders, capsules or suspensions. The present invention accordingly provides as another feature of it, pharmaceutical compositions containing, as the active ingredient, a cyclodextrin clathrate of prostaglandins of the present invention in association with a pharmaceutical carrier.

WHAT WE CLAIM IS:—

1. Cyclodextrin clathrates of PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1α} and PGA₁.
2. β-Cyclodextrin clathrates of PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1α} and PGA₁.
3. Cyclodextrin clathrates of a prostaglandin according to claim 1 or 2 in which the prostaglandin content of the clathrate is from 2% to 12% by weight of the clathrate.
4. A process for the production of a cyclodextrin clathrate of a prostaglandin as claimed in claim 1 which comprises reacting PGE₁,

15-methyl-PGE₁, 16-methyl-PGE₁(B), 17-methyl-PGE₁(B), PGF_{1α} or PGA₁, with cyclodextrin.

5. A process according to claim 4 in which a solution of the cyclodextrin in water and/or in an organic solvent which is miscible with water is added to a solution of the prostaglandin in an organic solvent which is miscible with water, the mixture is heated at a temperature below 70° C., and the resulting cyclodextrin clathrate of the prostaglandin is separated from the reaction mixture.

6. A process according to claim 5 in which the prostaglandin is PGE₁, 15-methyl-PGE₁, 16-methyl-PGE₁(B) or 17-methyl-PGE₁(B) and the reaction is carried out at a temperature of 20—60° C.

7. A process according to claim 5 or 6 in which the organic solvent is ethanol.

8. A process according to any one of claims 4 to 7 in which the molar ratio of prostaglandin to cyclodextrin in the reaction mixture is 1:4 to 12.

9. A process according to any one of claims 4 to 8 in which the cyclodextrin is β-cyclodextrin.

10. A process for the production of cyclodextrin clathrates of prostaglandins according to claim 4 substantially as hereinbefore described in any one of Examples 1 to 6.

11. Cyclodextrin clathrates of prostaglandins as claimed in claim 1 when produced by the process claimed in any one of claims 4 to 10.

- 5 12. Pharmaceutical compositions which comprise, as active ingredient, a cyclodextrin clathrate of a prostaglandin as claimed in claim 1, 2 or 3 in association with a pharmaceutically acceptable carrier.

J. A. [REDACTED] & CO.,
Chartered Patent Agents,
14, South Square,
Gray's Inn, London, W.C.1.

Reference has been directed in pursuance of Section 9, Subsection (1) of the Patents Act 1949, to Patent No. 1,097,157.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1975.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.